Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jill M. Van Dalfsen"'
Autor:
David P. Nichols, Sarah J. Morgan, Michelle Skalland, Anh T. Vo, Jill M. Van Dalfsen, Sachinkumar B.P. Singh, Wendy Ni, Lucas R. Hoffman, Kailee McGeer, Sonya L. Heltshe, John P. Clancy, Steven M. Rowe, Peter Jorth, Pradeep K. Singh, the PROMISE-Micro Study Group
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 10 (2023)
Background Lung infections are among the most consequential manifestations of cystic fibrosis (CF) and are associated with reduced lung function and shortened survival. Drugs called CF transmembrane conductance regulator (CFTR) modulators improve act
Externí odkaz:
https://doaj.org/article/f38c402d2a6340749497b7d56e6094d6
Autor:
Joseph M. Pilewski, Eugene C. Nelson, Jill M. Van Dalfsen, George Z. Retsch-Bogart, Bonnie W. Ramsey, Cynthia George, Bruce C. Marshall, Christopher H. Goss
Publikováno v:
Journal of General Internal Medicine. 29:714-723
Bringing new therapies to patients with rare diseases depends in part on optimizing clinical trial conduct through efficient study start-up processes and rapid enrollment. Suboptimal execution of clinical trials in academic medical centers not only r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d7e126562d733e73f9babf755a6f2f4
https://doi.org/10.1007/s11606-014-2896-8
https://doi.org/10.1007/s11606-014-2896-8
Autor:
Scott H. Donaldson, Tanja Gonska, Bonnie W. Ramsey, Scott D. Sagel, Umer Khan, Drucy Borowitz, Jill M. Van Dalfsen, Nicole Mayer-Hamblett, Steven M. Rowe, Daniel Gelfond, Elizabeth Joseloff, Sonya L. Heltshe
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 190:175-184
Rationale: Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator recently approved for patients with CF age 6 and older with the G551D mutation. Objectives: To evaluate ivacaftor in a postapproval setting and determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b70e55ac7a7ed9e4e9fb6effe3fed3c
https://doi.org/10.1164/rccm.201404-0703oc
https://doi.org/10.1164/rccm.201404-0703oc
Publikováno v:
Journal of the Pediatric Infectious Diseases Society. 4:151-154
Chronic antibiotic suppression of cystic fibrosis (CF) infections has increased in the United States, as has isolation of Pseudomonas aeruginosa with reduced antibiotic susceptibility. However, analysis of the susceptibilities of 193 initial P aerugi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::843b9e8e94c949829ba6a8e696c77e0d
https://doi.org/10.1093/jpids/pit052
https://doi.org/10.1093/jpids/pit052
Autor:
Melissa A. Ashlock, Robert J. Beall, Preston W. Campbell, Bonnie W. Ramsey, Christopher M. Penland, Michael W. Konstan, Jill M. Van Dalfsen, Diana R. Wetmore, Nicole M. Hamblett
Publikováno v:
Seminars in Respiratory and Critical Care Medicine. 30:611-626
Therapeutics development for cystic fibrosis (CF) involves a coordinated effort among many groups, including individuals with CF and their caregivers, clinical research teams, and those in academia and industry who have discovered and developed the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d295ca54f4e9edd7959fbb85dcdd695
https://doi.org/10.1055/s-0029-1238919
https://doi.org/10.1055/s-0029-1238919
Publikováno v:
Journal of Clinical Microbiology. 40:2791-2794
The microscopic examination of Gram-stained sputum specimens is very helpful in the evaluation of patients with community-acquired pneumonia and has also been recommended for use in cystic fibrosis (CF) patients. This study was undertaken to evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7271ab3af19e8d151affd82774e30a9f
https://doi.org/10.1128/jcm.40.8.2791-2794.2002
https://doi.org/10.1128/jcm.40.8.2791-2794.2002
Publikováno v:
Journal of Clinical Microbiology. 40:26-30
A culture method utilizing quantitative plating on antibiotic-containing media has been proposed as a technique for the detection of tobramycin-resistant organisms that is more sensitive than standard methods. Typical sputum culture methods quantitat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::389184408cf2b0cae22e83e8d84e2f56
https://doi.org/10.1128/jcm.40.1.26-30.2002
https://doi.org/10.1128/jcm.40.1.26-30.2002
How much doPseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?
Publikováno v:
Pediatric Pulmonology. 39:504-506
Recent studies suggest that chronic Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) involve anaerobic biofilms, and that these biofilms are the reason chronic infections are rarely eradicated by antibiotic therapy, regardless of the in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d27129f37d399a9667cd8db59a334b08
https://doi.org/10.1002/ppul.20220
https://doi.org/10.1002/ppul.20220
Autor:
Jonathan Ilowite, Heather Tully, Alan F. Barker, Leslie Couch, Jack O. Stewart, Anne O'Donnell, Tammy Abuan, Stanley B. Fiel, Lewis J. Smith, Steven A. Sahn, Jill M. Van Dalfsen, Mark H. Gotfried, Joanne Quan, Keith C. Meyer, Charles D. Wells
Publikováno v:
American journal of respiratory and critical care medicine. 162(2 Pt 1)
We conducted a placebo-controlled, double-blind, randomized study to evaluate the microbiological efficacy and safety of inhaled tobramycin for treatment of patients with bronchiectasis and Pseudomonas aeruginosa. Patients were randomly assigned to r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4864e5cbed1387fb0b06659ff9cc258
https://pubmed.ncbi.nlm.nih.gov/10934074
https://pubmed.ncbi.nlm.nih.gov/10934074
Autor:
Richard L. Garber, Joanne M. Quan, Kelly L. Otto, Bonnie W. Ramsey, Jane L. Burns, Arnold L. Smith, A. Bruce Montgomery, Gary M. Albers, Jill M. Van Dalfsen, Ribhi M. Shawar
Publikováno v:
The Journal of infectious diseases. 179(5)
Pseudomonas aeruginosa endobronchial infection causes significant morbidity and mortality among cystic fibrosis patients. Microbiology results from two multicenter, double-blind, placebo-controlled trials of inhaled tobramycin in cystic fibrosis were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bf249c36306d0c6d3fa455f853b049f
https://pubmed.ncbi.nlm.nih.gov/10191222
https://pubmed.ncbi.nlm.nih.gov/10191222